PL2142570T3 - Przeciwciała skierowane przeciw EPCAM i ich zastosowania - Google Patents

Przeciwciała skierowane przeciw EPCAM i ich zastosowania

Info

Publication number
PL2142570T3
PL2142570T3 PL08759374T PL08759374T PL2142570T3 PL 2142570 T3 PL2142570 T3 PL 2142570T3 PL 08759374 T PL08759374 T PL 08759374T PL 08759374 T PL08759374 T PL 08759374T PL 2142570 T3 PL2142570 T3 PL 2142570T3
Authority
PL
Poland
Prior art keywords
epcam antibody
therapeutic
designated
high affinity
shows high
Prior art date
Application number
PL08759374T
Other languages
English (en)
Polish (pl)
Inventor
Anna Maria Anastasi
Fiorella Petronzelli
Santis Rita De
Saverio Alberti
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of PL2142570T3 publication Critical patent/PL2142570T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL08759374T 2007-04-04 2008-04-02 Przeciwciała skierowane przeciw EPCAM i ich zastosowania PL2142570T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07105628 2007-04-04
EP08759374A EP2142570B1 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof
PCT/EP2008/053913 WO2008122551A2 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof

Publications (1)

Publication Number Publication Date
PL2142570T3 true PL2142570T3 (pl) 2011-11-30

Family

ID=38458122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08759374T PL2142570T3 (pl) 2007-04-04 2008-04-02 Przeciwciała skierowane przeciw EPCAM i ich zastosowania

Country Status (21)

Country Link
US (1) US8318911B2 (enExample)
EP (1) EP2142570B1 (enExample)
JP (1) JP5631733B2 (enExample)
KR (1) KR101683884B1 (enExample)
CN (1) CN101970497B (enExample)
AT (1) ATE512988T1 (enExample)
AU (1) AU2008235566B2 (enExample)
BR (1) BRPI0810096A8 (enExample)
CA (1) CA2682296C (enExample)
CY (1) CY1111819T1 (enExample)
DK (1) DK2142570T3 (enExample)
EA (1) EA023679B1 (enExample)
ES (1) ES2367675T3 (enExample)
HR (1) HRP20110620T1 (enExample)
IL (1) IL201196A0 (enExample)
MX (1) MX2009010444A (enExample)
PL (1) PL2142570T3 (enExample)
PT (1) PT2142570E (enExample)
RS (1) RS52040B (enExample)
SI (1) SI2142570T1 (enExample)
WO (1) WO2008122551A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5686493B2 (ja) 2003-01-24 2015-03-18 ユニバーシティ・オブ・ユタＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｕｔａｈ テロメアの長さを決定することによって死亡の危険性を予測する方法
CN102439171B (zh) 2008-12-22 2017-07-14 犹他大学研究基金会 单色多重定量pcr
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
CN107315086B (zh) * 2011-06-29 2019-09-10 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9494500B2 (en) 2012-10-29 2016-11-15 Academia Sinica Collection and concentration system for biologic substance of interest and use thereof
HK1220737A1 (zh) 2013-05-22 2017-05-12 Telomere Diagnostics, Inc. 短端粒丰度的量度
WO2015153816A2 (en) 2014-04-01 2015-10-08 Academia Sinica Methods and systems for cancer diagnosis and prognosis
EP2998026B1 (en) 2014-08-26 2024-01-17 Academia Sinica Collector architecture layout design
CA2971169A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
WO2017023704A1 (en) * 2015-07-31 2017-02-09 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
AU2017301826A1 (en) 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
TW202039582A (zh) * 2019-04-22 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ＥｐＣＡＭ抗體及其應用
US11851499B2 (en) 2019-06-11 2023-12-26 Bioatla, Inc. Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
JP7570653B2 (ja) * 2020-08-19 2024-10-22 ▲蘇▼州易慕峰生物科技有限公司 ヒト化抗体、キメラ抗原受容体、核酸、ベクター、細胞及び応用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JP3427871B2 (ja) * 1996-06-24 2003-07-22 戸田工業株式会社 コバルト被着型針状磁性酸化鉄粒子粉末
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b

Also Published As

Publication number Publication date
PT2142570E (pt) 2011-09-13
CA2682296C (en) 2017-02-28
DK2142570T3 (da) 2011-10-03
AU2008235566A1 (en) 2008-10-16
EA023679B1 (ru) 2016-06-30
BRPI0810096A2 (pt) 2014-10-21
BRPI0810096A8 (pt) 2017-12-26
CN101970497B (zh) 2017-05-10
SI2142570T1 (sl) 2012-01-31
WO2008122551A9 (en) 2009-02-05
KR101683884B1 (ko) 2016-12-07
EP2142570B1 (en) 2011-06-15
HRP20110620T1 (hr) 2011-09-30
RS52040B (sr) 2012-04-30
IL201196A0 (en) 2010-05-17
US20100092491A1 (en) 2010-04-15
KR20100016237A (ko) 2010-02-12
WO2008122551A3 (en) 2008-12-04
EP2142570A2 (en) 2010-01-13
EA200970923A1 (ru) 2010-04-30
ATE512988T1 (de) 2011-07-15
WO2008122551A2 (en) 2008-10-16
AU2008235566B2 (en) 2013-06-06
JP2010523096A (ja) 2010-07-15
CY1111819T1 (el) 2015-10-07
US8318911B2 (en) 2012-11-27
CA2682296A1 (en) 2008-10-16
JP5631733B2 (ja) 2014-11-26
CN101970497A (zh) 2011-02-09
MX2009010444A (es) 2009-10-20
ES2367675T3 (es) 2011-11-07

Similar Documents

Publication Publication Date Title
IL201196A0 (en) Anti-epcam antibody and uses thereof
GEAP202215050A (en) Antibodies against signal-regulatory protein alpha and methods of use
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
MX2024015039A (es) Composiciones anti-cd24 y usos de las mismas
TW200510459A (en) RG1 antibodies and uses thereof
UA113712C2 (xx) Антитіло до fap і способи його застосування
TW200732349A (en) Anti-OX40L antibodies and methods using same
EP4364754A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
EP4434543A3 (en) Human igg1 fc region variants and uses thereof
NZ600143A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
NZ603271A (en) Anti-erbb3 antibodies
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
IL214325A (en) Antibody against cmet, a drug that includes and uses it
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
EP2402373A3 (en) Anti-EphB4 Antibodies and Methods Using Same
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
EP4512830A3 (en) Antibodies useful in cancer diagnosis
WO2017015634A3 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
WO2010034825A3 (en) Novel antibodies recognizing native annexin a3
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.